

Almirall's Chairman, Carlos Gallardo, appointed as Interim CEO

- **Gianfranco Nazzi to leave the CEO role to pursue new opportunities**

Barcelona (Spain), November 03, 2022.- Gianfranco Nazzi, CEO, has stepped down effective November 2nd from his role as CEO at Almirall to pursue new professional opportunities. The Board has appointed Carlos Gallardo, Chairman of the Board of Directors, as acting CEO while the company identifies the best suitable candidate to succeed Gianfranco.

Carlos Gallardo, Chairman of the Board of Directors, commented:

"On behalf of the Board of Directors of Almirall and the broader leadership team, I would like to thank Gianfranco for his dedication and the contributions he has made as CEO of Almirall. He joined us at a crucial moment and achieved strong results, maximizing the value of our product launches, attracting key talent, and preparing Almirall for the next growth phase. We wish him every success for his future.

There are great things happening in the company right now: the sustained growth of Ilumetri, the strong uptake of the recently launched Klisyri and Wynzora, and the excellent clinical data on lebrikizumab, the regulatory dossier of which has now been accepted for filing by the EMA. We can be proud to have such a late-stage pipeline which, together with the talented people we have in the company, provide a great basis for continued growth.

I am delighted with the progress the whole Almirall team is making in transforming the company into a leader in the field of Medical Dermatology. Helping patients suffering from severe dermatological conditions will continue to be at the centre of everything we do".

The process to identify the CEO successor has already been set in motion.

About Almirall

Almirall is a global biopharmaceutical company focused on skin health. We collaborate with scientists and healthcare professionals to address patient's needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1943 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has retained a strong focus on the needs of patients. Currently, Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenues in 2021 were 836.5 million euros.

For more information, please visit www.almirall.com

Media contact Almirall:

Tinkle
Laura Blázquez
lblazquez@tinkle.es
Phone: (+34) 600 430 581

Corporate Communications contact:

Almirall
Mar Ramírez
mar.ramirez@almirall.com
Phone: (+34) 659 61 41 73

Investors' Relations contact

Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 3087

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the Company considers reasonable. These statements involve risks and uncertainties beyond the control of the Company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The Company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events, or circumstances on which such forward-looking statements are based, unless required by the applicable law.